News Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history. Synendos Therapeutics Appoints Scientific Advisory Board by Sunstone Life Science Ventures | Oct 26, 2021 Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, today announces the appointment of well renowned CNS experts to form its... MinervaX provides clinical and leadership update by Sunstone Life Science Ventures | Oct 7, 2021 MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces clinical progress on its maternal GBS vaccine as well as multiple additions to its leadership teams. MinervaX is developing a... Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF® by Sunstone Life Science Ventures | Sep 22, 2021 Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical study in gastric... Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial) by Sunstone Life Science Ventures | Aug 19, 2021 Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. Myelofibrosis, a... Synendos Therapeutics Expands Series A to CHF 24 million with new investment by Sunstone Life Science Ventures | Apr 20, 2021 Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capital’s contribution brings the total raised to CHF 24 million, following a Series A financing... Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy by Sunstone Life Science Ventures | Apr 16, 2021 Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research collaboration with MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based... Side 1 af 812345...»Sidste » Supported by: Member of: Cookie Policy Privacy Policy CSR Policy Tax Policy ESG Disclosures · No consideration of sustainability adverse impacts Design TR-Media ApS ©2021